Core Insights - Cogent Biosciences announced additional clinical results from the SUMMIT trial for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM), showing significant improvements across primary and secondary endpoints [1][2] Group 1: Clinical Results - Bezuclastinib demonstrated a mean change of -32.0 points in Total Symptom Score (TSS) at 48 weeks, indicating a 56% relative improvement from baseline [5][6] - 99% of patients achieved over 50% reduction in serum tryptase levels, with 83% normalizing their levels [6][11] - Significant improvements were observed across various symptoms, including a 65% reduction in dermatologic symptoms and a 53.6% reduction in neurocognitive symptoms [4][11] Group 2: Safety and Tolerability - Bezuclastinib exhibited a favorable safety and tolerability profile, supporting its potential for chronic use in NonAdvSM patients [7][11] Group 3: Market Position and Future Potential - The company believes bezuclastinib has the potential to become the preferred standard of care for NonAdvSM patients due to its rapid and meaningful symptom improvement [2][10] - The treatment is positioned as the first disease-modifying agent for NonAdvSM, with strong evidence correlating serum tryptase reduction with symptomatic improvement [5][11] Group 4: Inducement Grants - Cogent announced inducement equity awards to three new employees, including nonqualified options to purchase 24,000 shares and 21,000 restricted stock units (RSUs) [8]

Core Insights - Cogent Biosciences, Inc. is experiencing significant momentum entering 2026, driven by multiple regulatory catalysts and positive trial results for its lead product, bezuclastinib, targeting genetically defined diseases [2] Recent Company Highlights - The SUMMIT NDA for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) was submitted in December 2025, with the APEX NDA submission for patients with Advanced Systemic Mastocytosis (AdvSM) on track for the first half of 2026 [4] - The PEAK NDA for bezuclastinib in patients with second-line Gastrointestinal Stromal Tumors (GIST) has been initiated under the FDA's Real-Time Oncology Review (RTOR) program, with completion expected by April 2026 [4] - Six abstracts from the SUMMIT trial have been accepted for presentation at the 2026 AAAAI annual meeting, highlighting the clinical benefits of bezuclastinib [5] Financial Position - As of December 31, 2025, Cogent had cash, cash equivalents, and marketable securities totaling $900.8 million, sufficient to fund operations into 2028 [4][22] - Research and development expenses for Q4 2025 were $75.6 million, up from $62.0 million in Q4 2024, driven by ongoing pivotal trials and NDA filings [12] - General and administrative expenses for Q4 2025 were $23.9 million, compared to $11.7 million in Q4 2024, reflecting organizational growth and preparations for the commercial launch of bezuclastinib [13] Clinical Trial Results - The SUMMIT trial demonstrated clear clinical benefits across all symptom domains in NonAdvSM patients, with significant improvements in 11 individual symptoms and a reduction in serum tryptase levels [5] - The APEX trial reported an objective response rate of 57% per mIWG criteria and 80% per PPR criteria, with 89% of patients achieving a ≥50% reduction in bone marrow mast cells [5] Upcoming Milestones - The company plans to submit the APEX NDA in the first half of 2026 and complete the PEAK NDA submission by April 2026 [9] - Detailed clinical data from the PEAK and APEX trials will be presented at major medical meetings during the first half of 2026 [9]

Core Insights - Cogent Biosciences, Inc. is set to present multiple posters on bezuclastinib results from the SUMMIT trial for NonAdvanced Systemic Mastocytosis at the 2026 AAAAI Annual Meeting [1][2] Group 1: Upcoming Presentations - The posters will cover various aspects of bezuclastinib, including expanded results from the Phase 2 SUMMIT trial, evaluation of bone formation marker changes, patient experiences, symptom burden improvement, and results in subgroups with unmet needs [3] Group 2: Drug Development and Regulatory Status - In December 2025, Cogent submitted a New Drug Application for bezuclastinib to the FDA, based on positive clinical data from the SUMMIT trial and following its Breakthrough Therapy Designation [2] - Bezuclastinib is a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which is significant in systemic mastocytosis and other related conditions [4] Group 3: Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases and has an ongoing Phase 1 study of a novel FGFR2/3 inhibitor [4][5]

Company Overview - Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases [3] - The company is based in Waltham, MA and Boulder, CO [3] Key Developments - Andrew Robbins, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [1] - A live webcast of the presentation will be available on the Investors & Media page of Cogent's website, with a replay accessible for 30 days post-event [2] Clinical Programs - The most advanced clinical program is bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which is linked to systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST) [3] - The company is also conducting a Phase 1 study of a novel internally discovered FGFR2/3 inhibitor [3] - Cogent is developing a portfolio of targeted therapies aimed at mutations in ErbB2, PI3Kα, KRAS, and JAK2 [3]

Core Insights - Cogent Biosciences has submitted a New Drug Application (NDA) for bezuclastinib to the FDA for NonAdvanced Systemic Mastocytosis (NonAdvSM), based on positive results from the SUMMIT pivotal trial [1][2] - The NDA submission is part of a broader strategy, with two additional submissions planned for bezuclastinib targeting Gastrointestinal Stromal Tumors (GIST) and Advanced Systemic Mastocytosis (AdvSM) in the first half of 2026 [5] Group 1: Clinical Data and Trial Results - The SUMMIT trial achieved statistical significance across all primary and key secondary endpoints, demonstrating the efficacy of bezuclastinib in patients with NonAdvSM [2] - Bezuclastinib showed significant clinical benefits across 11 individual patient-reported symptoms, with reductions in serum tryptase correlating with symptom severity improvements [3] - Updated data from the SUMMIT trial indicated a continued deepening of symptomatic improvement over 48 weeks, suggesting potential for sustained clinical benefits with longer therapy duration [4] Group 2: Regulatory Designation and Future Plans - Bezuclastinib received Breakthrough Therapy Designation from the FDA in October 2025, highlighting its potential to meet significant unmet medical needs [5] - The company plans to submit NDAs for bezuclastinib in GIST and AdvSM based on strong clinical results from the PEAK and APEX trials, expected in the first half of 2026 [5] Group 3: Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with bezuclastinib being a selective tyrosine kinase inhibitor targeting the KIT D816V mutation [6] - The company is also engaged in developing a portfolio of novel targeted therapies for serious, genetically driven diseases, including ongoing studies for FGFR2/3 inhibitors [6]

Core Viewpoint - Cogent Biosciences, Inc. has initiated public offerings totaling $400 million, comprising $200 million in convertible senior notes and $200 million in common stock to support its operations and product development [1][5]. Offering Details - The company is offering $200 million in convertible senior notes due 2031 and $200 million in common stock, with underwriters granted a 30-day option to purchase an additional $30 million in each offering [1][2]. - The convertible notes will be unsecured, with interest payable semi-annually, maturing on November 15, 2031, and can be converted into cash, shares, or a combination thereof [4]. Use of Proceeds - Net proceeds from the offerings will be allocated to repay $50 million in existing loans, development and regulatory activities for bezuclastinib and other candidates, and general corporate purposes [5]. Management and Underwriters - Jefferies and J.P. Morgan are the joint book-running managers for the convertible notes offering, while multiple firms including J.P. Morgan and Jefferies are managing the equity offering [6]. Regulatory Compliance - The offerings will be conducted under an automatic shelf registration statement filed with the SEC, which became effective upon filing [7].

Core Insights - Cogent Biosciences is approaching significant milestones with the upcoming top-line results from the Phase 3 PEAK trial in November 2025 and the APEX trial in December 2025 [1][4][13] - The company has received Breakthrough Therapy Designation for bezuclastinib, which is on track for a New Drug Application (NDA) submission for NonAdvanced Systemic Mastocytosis (NonAdvSM) by the end of 2025 [1][5][12] - Cogent has a strong cash position of $430 million, expected to fund operations through the anticipated launch of bezuclastinib and into 2027 [1][6] Recent Business Highlights - The company reported positive top-line results from the SUMMIT trial, achieving statistical significance across all primary and key secondary endpoints for NonAdvSM patients [5] - Cogent plans to present multiple abstracts at the 67th Annual Meeting of the American Society of Hematology (ASH) in December 2025, including two oral presentations on SUMMIT data [1][5][2] - The company has received FDA clearance for its Investigational New Drug (IND) submission for CGT4255, a novel ErbB2 inhibitor, with a Phase 1 trial set to begin in November [5] Financial Overview - As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $390.9 million, an increase from $345.5 million as of June 30, 2025 [6] - Research and development expenses for Q3 2025 were $69.0 million, up from $63.6 million in Q3 2024, primarily due to ongoing clinical trials [7] - General and administrative expenses rose to $14.4 million in Q3 2025 from $11.8 million in Q3 2024, reflecting organizational growth [8] - The net loss for Q3 2025 was $80.9 million, compared to a net loss of $70.6 million for the same period in 2024 [9]

Core Insights - Cogent Biosciences, Inc. announced multiple presentations for bezuclastinib at the upcoming 67th Annual Meeting of the American Society of Hematology (ASH), highlighting its potential as a best-in-class treatment for NonAdvanced Systemic Mastocytosis (NonAdvSM) [1][2] - The company is also set to present a novel JAK2 V617F mutant-selective inhibitor, which is expected to be on track for an Investigational New Drug (IND) application in 2026 [1][2] Presentation Details - Bezuclastinib will be featured in two oral presentations at ASH, focusing on its efficacy and safety results from the pivotal Summit trial in adults with NonAdvSM [3] - The first oral presentation will take place on December 6, 2025, at 9:45 AM ET, presented by Dr. Lindsay Rein [3] - The second oral presentation will discuss the effects of bezuclastinib on mastocytosis pathobiology, scheduled for December 8, 2025, at 5:00 PM ET, presented by Dr. Tracy George [4] Additional Research - A poster presentation will explore the relationship between KIT inhibition by bezuclastinib and its effects on disease burden in mouse models of systemic mastocytosis, scheduled for December 8, 2025 [5] - Preclinical data on the novel JAK2 V617F mutant-selective inhibitor will also be presented in a poster session on December 7, 2025 [6] Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with bezuclastinib being a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which drives systemic mastocytosis [7] - The company is also developing a portfolio of targeted therapies aimed at various mutations, including FGFR2/3, ErbB2, PI3Kα, KRAS, and JAK2 [7]

Core Insights - Cogent Biosciences, Inc. presented updated preclinical data on its pan KRAS(ON) inhibitor at the 2025 AACR-NCI-EORTC International Conference, indicating a potential best-in-class profile for its lead molecule [1][2] Group 1: Product Development - The pan KRAS(ON) program aims to file an Investigational New Drug (IND) application with the FDA in 2026 [2] - The presented data highlights CGT1263, a potent KRAS inhibitor, demonstrating selectivity for mutant KRAS over HRAS and NRAS, with picomolar activity across various KRAS mutant cell lines [3] - CGT1815, the prodrug of CGT1263, is designed to optimize pharmacokinetic performance, showing superior efficacy in tumor growth inhibition studies compared to RMC-6236 [3] Group 2: Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with its most advanced clinical program being bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation [4] - The company is also conducting a Phase 1 study of a novel FGFR2/3 inhibitor and developing therapies targeting mutations in ErbB2, PI3Kα, and KRAS [4]

Core Insights - Cogent Biosciences, Inc. presented updated preclinical data on its pan KRAS(ON) inhibitor at the 2025 AACR-NCI-EORTC International Conference, indicating a potential best-in-class profile for its lead molecule [1][2] Group 1: Product Development - The pan KRAS(ON) program aims to file an Investigational New Drug (IND) application with the FDA in 2026 [2] - The presented data highlights the KRAS(ON/OFF) inhibitor CGT1263, which shows selectivity for mutant KRAS over HRAS and NRAS, with picomolar activity across various KRAS mutant cell lines [3] - CGT1815, the prodrug of CGT1263, is designed to enhance human pharmacokinetic performance, demonstrating superior efficacy in tumor growth inhibition studies compared to RMC-6236 [3] Group 2: Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with its most advanced clinical program being bezuclastinib, a selective tyrosine kinase inhibitor targeting the KIT D816V mutation [4] - The company is also conducting a Phase 1 study of a novel FGFR2/3 inhibitor and developing therapies targeting mutations in ErbB2, PI3Kα, and KRAS [4]